Zobrazeno 1 - 10
of 307
pro vyhledávání: '"Martin, Fleisher"'
Autor:
Hong Li, Chi‐Ling Chiang, Kwang Joo Kwak, Xinyu Wang, Sital Doddi, Lakshmi V. Ramanathan, Sun M. Cho, Ya‐Chin Hou, Tai‐Shan Cheng, Xiaokui Mo, Yueh‐Shih Chang, Hui‐Lan Chang, Weiming Cheng, Wei‐Ni Tsai, Luong T. H. Nguyen, Junjie Pan, Yifan Ma, Xilal Y. Rima, Jingjing Zhang, Eduardo Reategui, Yeh‐Shiu Chu, Peter Mu‐Hsin Chang, Pei‐Hung Chang, Chi‐Ying F. Huang, Cheng‐Hsu Wang, Yan‐Shen Shan, Chung‐Pin Li, Martin Fleisher, L. James Lee
Publikováno v:
Advanced Science, Vol 11, Iss 11, Pp n/a-n/a (2024)
Abstract Detecting pancreatic duct adenocarcinoma (PDAC) in its early stages and predicting late‐stage patient prognosis undergoing chemotherapy is challenging. This work shows that the activation of specific oncogenes leads to elevated expression
Externí odkaz:
https://doaj.org/article/a765cae34104438aa7abecd26a692173
Autor:
Tiffany Y. Sia, Zvi Yaari, Ron Feiner, Evan Smith, Arnaud Da Cruz Paula, Pier Selenica, Sital Doddi, Dennis S. Chi, Nadeem R. Abu-Rustum, Douglas A. Levine, Britta Weigelt, Martin Fleisher, Lakshmi V. Ramanathan, Daniel A. Heller, Kara Long Roche
Publikováno v:
Gynecologic Oncology Reports, Vol 51, Iss , Pp 101330- (2024)
Given the tubal origin of high-grade serous ovarian cancer (HGSC), we sought to investigate intrauterine lavage (IUL) as a novel method of biomarker detection. IUL and serum samples were collected from patients with HGSC or benign pathology. Although
Externí odkaz:
https://doaj.org/article/0ec9b8149c314a47adc99948d4bc2357
Autor:
Donata von Reibnitz, Ellen D. Yorke, Jung Hun Oh, Aditya P. Apte, Jie Yang, Hai Pham, Maria Thor, Abraham J. Wu, Martin Fleisher, Emily Gelb, Joseph O. Deasy, Andreas Rimner
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: To investigate the impact of alpha-2-macroglobulin (A2M), a suspected intrinsic radioprotectant, on radiation pneumonitis and esophagitis using multifactorial predictive models.Materials and Methods: Baseline A2M levels were obtained for
Externí odkaz:
https://doaj.org/article/3a901e89ef09431aaf202cc75acd8ef5
Autor:
Prasad S. Adusumilli, Valerie W. Rusch, Martin Fleisher, Hans Gerdes, Camelia S. Sima, Laura H. Tang, Elliot L. Servais, Nabil P. Rizk
PDF file - 76K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13ff44a8c51e7f5d789054f57a7fce62
https://doi.org/10.1158/1055-9965.22438072
https://doi.org/10.1158/1055-9965.22438072
Autor:
Prasad S. Adusumilli, Valerie W. Rusch, Martin Fleisher, Hans Gerdes, Camelia S. Sima, Laura H. Tang, Elliot L. Servais, Nabil P. Rizk
Background: Mesothelin is overexpressed in several malignancies and is purportedly a specific marker of malignant transformation. In this pilot study, we investigated whether tissue and serum mesothelin are potential markers of neoplastic progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07136bc086610c42bba657dfac0ed1e5
https://doi.org/10.1158/1055-9965.c.6516193.v1
https://doi.org/10.1158/1055-9965.c.6516193.v1
Autor:
Andrew D. Seidman, Larry Norton, Catherine Van Poznak, Martin Fleisher, Sujata Patil, Kendrick Tang, Bob T. Li, Margaret M. Kemeny, Elena Pentsova, Elisa de Stanchina, Aki Morikawa
Supplemental preclinical data background
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377d9a0105ff4c576af4bd6e10b46596
https://doi.org/10.1158/1078-0432.22472447
https://doi.org/10.1158/1078-0432.22472447
Autor:
Ryan Dittamore, Glenn Heller, Mark Landers, Martin Fleisher, Hebert A. Vargas, Lyndsey Dugan, Jessica E. Louw, Pascal Bamford, David Lu, Rachel Krupa, Stephanie Greene, Jerry Lee, Yipeng Wang, Adam Jendrisak, Brigit McLaughlin, Nicole A. Schreiber, Ryon P. Graf, Howard I. Scher
The heterogeneity of an individual patient's tumor has been linked to treatment resistance, but quantitative biomarkers to rapidly and reproducibly evaluate heterogeneity in a clinical setting are currently lacking. Using established tools available
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c402becdf1a2391aa635f0698de7c41
https://doi.org/10.1158/0008-5472.c.6509265.v1
https://doi.org/10.1158/0008-5472.c.6509265.v1
Autor:
Andrew D. Seidman, Larry Norton, Catherine Van Poznak, Martin Fleisher, Sujata Patil, Kendrick Tang, Bob T. Li, Margaret M. Kemeny, Elena Pentsova, Elisa de Stanchina, Aki Morikawa
Purpose:Lapatinib and capecitabine cross the blood–tumor barrier in breast cancer brain metastasis but have modest clinical efficacy. Administration of high-dose tyrosine kinase inhibitor has been evaluated in brain metastases and primary brain tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::371ae10916e1f0a5af4cedf20f65615e
https://doi.org/10.1158/1078-0432.c.6528221
https://doi.org/10.1158/1078-0432.c.6528221
Autor:
Daniel A. Haber, Mehmet Toner, Shyamala Maheswaran, Ravi Kapur, Shannon L. Stott, Jeffrey A. Engelman, John R. Walsh, Thomas A. Barber, Bruce E. Johnson, Wen Wei, Helena A. Yu, Martin Fleisher, Uma Giri, Hai T. Tran, Andrew Webb, Alona Muzikansky, Robert Maher, Douglas B. Fox, James P. Sullivan, Walter H. Koch, Pasi A. Jänne, Gregory J. Riely, John V. Heymach, Lecia V. Sequist, Tilak K. Sundaresan
Supplementary tables S1-S3. Supplementary Table S1: Institutional Tumor Genotyping Strategies. Supplementary Table S2: T790M Genotype by Modality. Supplementary Table S3: EGFR Primary Mutation Detection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::872af2d4534314744579a6b80c0fd5be
https://doi.org/10.1158/1078-0432.22457103.v1
https://doi.org/10.1158/1078-0432.22457103.v1
Autor:
Daniel A. Haber, Mehmet Toner, Shyamala Maheswaran, Ravi Kapur, Shannon L. Stott, Jeffrey A. Engelman, John R. Walsh, Thomas A. Barber, Bruce E. Johnson, Wen Wei, Helena A. Yu, Martin Fleisher, Uma Giri, Hai T. Tran, Andrew Webb, Alona Muzikansky, Robert Maher, Douglas B. Fox, James P. Sullivan, Walter H. Koch, Pasi A. Jänne, Gregory J. Riely, John V. Heymach, Lecia V. Sequist, Tilak K. Sundaresan
Purpose: The T790M gatekeeper mutation in the EGFR is acquired by some EGFR-mutant non–small cell lung cancers (NSCLC) as they become resistant to selective tyrosine kinase inhibitors (TKI). As third-generation EGFR TKIs that overcome T790M-associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::045e97714a002cfa707153c4c4fce05c
https://doi.org/10.1158/1078-0432.c.6523506
https://doi.org/10.1158/1078-0432.c.6523506